<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140906</url>
  </required_header>
  <id_info>
    <org_study_id>13267A</org_study_id>
    <secondary_id>2009-017523-26</secondary_id>
    <nct_id>NCT01140906</nct_id>
  </id_info>
  <brief_title>Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults</brief_title>
  <official_title>A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Lu AA21004 (15 and 20 mg/Day) in the Acute Treatment of Adult Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, tolerability and the safety of two
      fixed doses of vortioxetine in the treatment of major depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Responders at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Status Using CGI-I Score at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score &lt;=10)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDS Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ASEX Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, &quot;How strong is your sex drive?&quot;, &quot;Are your orgasms satisfying?&quot;) and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine</measure>
    <time_frame>Change from Week 8 in DESS total score analyzed at Week 10</time_frame>
    <description>The Discontinuation-Emergent Signs and Symptoms Scale (DESS) was designed to evaluate possible effects of discontinuation of antidepressant therapy. It is a clinician-rated instrument that queries for signs and symptoms on a 43-item checklist (for example, agitation, insomnia, fatigue, and dizziness) to assess whether the item (event) is discontinuation-emergent. A new or worsened event reported after discontinuation of therapy scores 1 point on the checklist, and the DESS total score is the sum of all positive scores on the checklist. A higher score indicates more symptoms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">607</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine: 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine: 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine: 60 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active Reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules, daily, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine (Lu AA21004)</intervention_name>
    <description>encapsulated tablets, daily, orally</description>
    <arm_group_label>Vortioxetine: 15 mg</arm_group_label>
    <arm_group_label>Vortioxetine: 20 mg</arm_group_label>
    <other_name>Brintellix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>encapsulated capsules, daily, orally</description>
    <arm_group_label>Duloxetine: 60 mg</arm_group_label>
    <other_name>Cymbalta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has recurrent MDD as the primary diagnosis according to DSM-IV-TR™
             criteria (classification code 296.3x)

          -  The patient has a MADRS total score &gt;=26

          -  The patient has a CGI-S score &gt;=4

          -  The patient has had the current episode of MDE for &gt;3 months

        Exclusion Criteria:

          -  Any current anxiety psychiatric disorder as defined in the DSM-IV TR

          -  Current diagnosis or history of manic or hypomanic episode, schizophrenia or any other
             psychotic disorder, including major depression with psychotic features, mental
             retardation, organic mental disorders, or mental disorders due to a general medical
             condition as defined in the DSM-IV TR

          -  Current diagnosis or history of alcohol or other substance abuse or dependence
             (excluding nicotine or caffeine) as defined in the DSM-IV TR

          -  Use of any psychoactive medication 2 weeks prior to screening and during the study

          -  The patient is at significant risk of suicide or has a score &gt;=5 on Item 10 (suicidal
             thoughts) of the MADRS, or has attempted suicide within 6 months prior to the
             Screening Visit

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <results_first_submitted>October 28, 2013</results_first_submitted>
  <results_first_submitted_qc>December 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2014</results_first_posted>
  <last_update_submitted>December 23, 2013</last_update_submitted>
  <last_update_submitted_qc>December 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major depressive disorder</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Active reference</keyword>
  <keyword>Multicenter study</keyword>
  <keyword>Randomised study</keyword>
  <keyword>Acute treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were selected from psychiatric settings (private practices), outpatient clinics, and inpatient hospitals.</recruitment_details>
      <pre_assignment_details>At the Baseline Visit, patients who fulfilled the selection criteria were assigned to treatment with either placebo, vortioxetine 15 or 20 mg/day, or duloxetine 60 mg/day in a 1:1:1:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>capsules, daily, orally</description>
        </group>
        <group group_id="P2">
          <title>Vortioxetine 15 mg</title>
          <description>encapsulated tablets, daily, orally</description>
        </group>
        <group group_id="P3">
          <title>Vortioxetine 20 mg</title>
          <description>encapsulated tablets, daily, orally</description>
        </group>
        <group group_id="P4">
          <title>Duloxetine 60 mg</title>
          <description>encapsulated capsules, daily, orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="125"/>
                <participants group_id="P4" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative or other reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>capsules, daily, orally</description>
        </group>
        <group group_id="B2">
          <title>Vortioxetine 15 mg</title>
          <description>encapsulated tablets, daily, orally</description>
        </group>
        <group group_id="B3">
          <title>Vortioxetine 20 mg</title>
          <description>encapsulated tablets, daily, orally</description>
        </group>
        <group group_id="B4">
          <title>Duloxetine 60 mg</title>
          <description>encapsulated capsules, daily, orally</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="158"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="151"/>
            <count group_id="B4" value="147"/>
            <count group_id="B5" value="607"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="13.1"/>
                    <measurement group_id="B2" value="47.0" spread="14.6"/>
                    <measurement group_id="B3" value="46.2" spread="13.4"/>
                    <measurement group_id="B4" value="45.6" spread="13.6"/>
                    <measurement group_id="B5" value="46.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MADRS baseline total score</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. 9 of the items are based on patient report, and 1 is based on the rater's observation of the patients. Total score from 0 to 60. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="3.6"/>
                    <measurement group_id="B2" value="31.8" spread="3.4"/>
                    <measurement group_id="B3" value="31.2" spread="3.4"/>
                    <measurement group_id="B4" value="31.2" spread="3.5"/>
                    <measurement group_id="B5" value="31.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI-S baseline severity score</title>
          <description>The Clinical Global Impression – Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="0.7"/>
                    <measurement group_id="B2" value="4.9" spread="0.6"/>
                    <measurement group_id="B3" value="4.8" spread="0.7"/>
                    <measurement group_id="B4" value="4.8" spread="0.7"/>
                    <measurement group_id="B5" value="4.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAM-A baseline total score</title>
          <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="6.6"/>
                    <measurement group_id="B2" value="21.3" spread="6.8"/>
                    <measurement group_id="B3" value="20.4" spread="6.9"/>
                    <measurement group_id="B4" value="20.5" spread="6.7"/>
                    <measurement group_id="B5" value="20.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SDS total baseline score</title>
          <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.8" spread="6.0"/>
                    <measurement group_id="B2" value="20.6" spread="5.3"/>
                    <measurement group_id="B3" value="20.7" spread="4.8"/>
                    <measurement group_id="B4" value="20.5" spread="4.4"/>
                    <measurement group_id="B5" value="20.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.</title>
        <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full-analysis set (FAS), mixed model for repeated measurements (MMRM)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 15 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment.</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.</description>
          <population>Full-analysis set (FAS), mixed model for repeated measurements (MMRM)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.70" spread="0.76"/>
                    <measurement group_id="O2" value="-17.23" spread="0.79"/>
                    <measurement group_id="O3" value="-18.79" spread="0.78"/>
                    <measurement group_id="O4" value="-21.15" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.66</ci_lower_limit>
            <ci_upper_limit>-3.40</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.21</ci_lower_limit>
            <ci_upper_limit>-4.97</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This treatment arm was not in the testing sequence. A nominal p-value is provided.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.55</ci_lower_limit>
            <ci_upper_limit>-7.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Responders at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</title>
        <time_frame>Week 8</time_frame>
        <population>FAS, last observation carried forward (LOCF), Logistic Regression</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 15 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Responders at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</title>
          <population>FAS, last observation carried forward (LOCF), Logistic Regression</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Wald's test. Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>Adjusted Odds Ratio</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Wald's test. Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>Adjusted Odds Ratio</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>5.36</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This treatment arm was not in the testing sequence. A nominal p-value is provided.</p_value_desc>
            <method>Adjusted Odds Ratio</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.61</ci_lower_limit>
            <ci_upper_limit>9.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Status Using CGI-I Score at Week 8</title>
        <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.</description>
        <time_frame>Week 8</time_frame>
        <population>FAS, MMRM</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 15 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Status Using CGI-I Score at Week 8</title>
          <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.</description>
          <population>FAS, MMRM</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="0.09"/>
                    <measurement group_id="O2" value="2.18" spread="0.09"/>
                    <measurement group_id="O3" value="1.92" spread="0.09"/>
                    <measurement group_id="O4" value="1.75" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.20</ci_lower_limit>
            <ci_upper_limit>-0.70</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This treatment arm was not in the testing sequence. A nominal p-value is provided.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>-0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20</title>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS, MMRM</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 15 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MADRS Total Score After 8 Weeks of Treatment in Patients With Baseline HAM-A Total Score ≥20</title>
          <population>FAS, MMRM</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.20" spread="1.09"/>
                    <measurement group_id="O2" value="-17.44" spread="1.08"/>
                    <measurement group_id="O3" value="-18.62" spread="1.15"/>
                    <measurement group_id="O4" value="-20.91" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.25</ci_lower_limit>
            <ci_upper_limit>-2.22</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.53</ci_lower_limit>
            <ci_upper_limit>-3.31</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This treatment arm was not in the testing sequence. A nominal p-value is provided.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.73</ci_lower_limit>
            <ci_upper_limit>-5.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score &lt;=10)</title>
        <time_frame>Week 8</time_frame>
        <population>FAS, LOCF, Logistic Regression</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 15 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score &lt;=10)</title>
          <population>FAS, LOCF, Logistic Regression</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <p_value_desc>Wald's test. Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>Adjusted Odds Ratio</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>3.91</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Wald's test. Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>Adjusted Odds Ratio</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.58</ci_lower_limit>
            <ci_upper_limit>4.44</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Wald's test. This treatment arm was not in the testing sequence. A nominal p-value is provided.</p_value_desc>
            <method>Adjusted for Odds Ratio</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.99</ci_lower_limit>
            <ci_upper_limit>8.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDS Total Score After 8 Weeks of Treatment</title>
        <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS, MMRM</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 15 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDS Total Score After 8 Weeks of Treatment</title>
          <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
          <population>FAS, MMRM</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.46" spread="0.82"/>
                    <measurement group_id="O2" value="-7.70" spread="0.89"/>
                    <measurement group_id="O3" value="-8.38" spread="0.85"/>
                    <measurement group_id="O4" value="-11.39" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0054</p_value>
            <p_value_desc>Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.51</ci_lower_limit>
            <ci_upper_limit>-0.97</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As soon as an endpoint was non-significant at the 0.025 level of significance, the testing procedure was stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Since p-value &lt;0.025, hierarchically testing continued.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.11</ci_lower_limit>
            <ci_upper_limit>-1.73</ci_upper_limit>
            <estimate_desc>To adjust for multiplicity the two doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.025.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This treatment arm was not in the testing sequence. A nominal p-value is provided.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.16</ci_lower_limit>
            <ci_upper_limit>-4.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ASEX Total Score After 8 Weeks of Treatment</title>
        <description>The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient’s recent sexual experience. Patients are asked to assess their own experience over the last week (for example, “How strong is your sex drive?”, “Are your orgasms satisfying?”) and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS, MMRM</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 15 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ASEX Total Score After 8 Weeks of Treatment</title>
          <description>The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient self-rated scale that evaluates a patient’s recent sexual experience. Patients are asked to assess their own experience over the last week (for example, “How strong is your sex drive?”, “Are your orgasms satisfying?”) and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction. A negative change indicates a lower sexual dysfunction.</description>
          <population>FAS, MMRM</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.42"/>
                    <measurement group_id="O2" value="-0.39" spread="0.43"/>
                    <measurement group_id="O3" value="-0.20" spread="0.43"/>
                    <measurement group_id="O4" value="-1.25" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2524</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4186</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.64</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>No correction for multiplicity was made.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine</title>
        <description>The Discontinuation-Emergent Signs and Symptoms Scale (DESS) was designed to evaluate possible effects of discontinuation of antidepressant therapy. It is a clinician-rated instrument that queries for signs and symptoms on a 43-item checklist (for example, agitation, insomnia, fatigue, and dizziness) to assess whether the item (event) is discontinuation-emergent. A new or worsened event reported after discontinuation of therapy scores 1 point on the checklist, and the DESS total score is the sum of all positive scores on the checklist. A higher score indicates more symptoms.</description>
        <time_frame>Change from Week 8 in DESS total score analyzed at Week 10</time_frame>
        <population>All Patients Completed Set (APCS), OC, Analysis of Covariance (ANCOVA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>capsules, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 15 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>encapsulated capsules, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Potential Discontinuation Symptoms After Abrupt Discontinuation of Treatment With Vortioxetine</title>
          <description>The Discontinuation-Emergent Signs and Symptoms Scale (DESS) was designed to evaluate possible effects of discontinuation of antidepressant therapy. It is a clinician-rated instrument that queries for signs and symptoms on a 43-item checklist (for example, agitation, insomnia, fatigue, and dizziness) to assess whether the item (event) is discontinuation-emergent. A new or worsened event reported after discontinuation of therapy scores 1 point on the checklist, and the DESS total score is the sum of all positive scores on the checklist. A higher score indicates more symptoms.</description>
          <population>All Patients Completed Set (APCS), OC, Analysis of Covariance (ANCOVA)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.30"/>
                    <measurement group_id="O2" value="0.01" spread="0.31"/>
                    <measurement group_id="O3" value="0.72" spread="0.31"/>
                    <measurement group_id="O4" value="2.28" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7372</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1690</p_value>
            <p_value_desc>A nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events: 8-week double-blind treatment period and 4-week safety follow-up period Other Adverse Events: 8-week double-blind treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Vortioxetine 15 mg</title>
        </group>
        <group group_id="E3">
          <title>Vortioxetine 20 mg</title>
        </group>
        <group group_id="E4">
          <title>Duloxetine 60 mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of this study will be published at the discretion of H. Lundbeck A/S. H. Lundbeck A/S will ensure that the authorship of all publications based on this study is in accordance with the criteria defined by the International Committee of Medical Journal Editors (ICMJE).
The primary publication must be published before any secondary publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Lundbeck A/S</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <phone>+45 3630 1311</phone>
      <email>LundbeckClinicalTrials@lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

